Bharat Biotech has partnered with Alopexx Inc. to co-develop and commercialize the broad-spectrum antimicrobial vaccine AV0328, targeting poly N-acetyl glucosamine (PNAG) found on various pathogens. This collaboration aims to address antimicrobial resistance (AMR) in India and other low-income countries, with Bharat Biotech committed to providing safe and affordable vaccine solutions. Alopexx will receive an upfront payment, milestone payments, and royalties from future sales of AV0328. The vaccine has shown promise in pre-clinical studies and completed a phase I trial with no serious adverse events reported. Both companies emphasize the importance of this venture in combating infectious diseases globally, with Bharat Biotech's executive chair highlighting the need for effective solutions in underserved regions. Alopexx's CEO expressed excitement over the collaboration, noting its significance in advancing their clinical programs and addressing critical healthcare needs.